Literature DB >> 12747596

The apolipoprotein AV gene and diurnal triglyceridaemia in normolipidaemic subjects.

Lluis Masana1, Josep Ribalta, Juliana Salazar, Joan Fernández-Ballart, Jorge Joven, Manuel Castro Cabezas.   

Abstract

The newly recognised apolipoprotein (apo) AV gene (APOAV) has been linked to fasting plasma triglyceride (TG) concentrations with some polymorphisms associated with elevated fasting TGs. Since fasting plasma TGs are mainly determined by the hepatic production of TG-rich particles (very low density lipoprotein; VLDL), and fasting TGs are the major determinants of postprandial lipaemia, we have evaluated the effects of an APOAV polymorphism on postprandial triglyceridaemia, which is largely determined by the intestinal production and clearance of chylomicrons. For this purpose, diurnal capillary triglyceridaemia (reflecting postprandial lipaemia) was determined in a cohort of 88 healthy volunteers (48 males and 40 females) in relation with a -1131T>C variant in the promoter of APOAV. Thirteen of these subjects (7 males and 6 females) were carriers of the -1131C allele, which has been associated with higher fasting plasma TG levels. The carriers had higher fasting capillary TG concentrations, although plasma TGs were not significantly different from non-carriers in this cohort. Surprisingly, total diurnal triglyceridaemia calculated as the area under the capillary TG curve was similar in carriers compared to non-carriers but after correction for fasting capillary TG levels, incremental diurnal triglyceridaemia was significantly lower in carriers (1.74 (5.27) mmol/h/l) than in non-carriers (4.91 (4.90) mmol/h/l; p = 0.036). The same trends were found for both males and females when analysed separately. Since dietary intake, which is a major determinant of incremental diurnal triglyceridaemia, did not differ between the two groups, we believe that these differences are at least partly explained by the APOAV. In summary, the APOAV assessed by means of the -1131T>C variant seemed to have a paradoxical effect on postprandial lipaemia when compared to fasting TG levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12747596     DOI: 10.1515/CCLM.2003.078

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

1.  Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor.

Authors:  Maxime Nowak; Audrey Helleboid-Chapman; Heidelinde Jakel; Geneviève Martin; Daniel Duran-Sandoval; Bart Staels; Edward M Rubin; Len A Pennacchio; Marja-Riitta Taskinen; Jamila Fruchart-Najib; Jean-Charles Fruchart
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

2.  Coronary risk factors and metabolic disorders in first-degree relatives of normocholesterolaemic patients with premature atherosclerosis.

Authors:  C A Geluk; C J M Halkes; P P Th De Jaegere; H W M Plokker; M Castro Cabezas
Journal:  Neth Heart J       Date:  2006-04       Impact factor: 2.380

3.  Interactions of the apolipoprotein A5 gene polymorphisms and alcohol consumption on serum lipid levels.

Authors:  Rui-Xing Yin; Yi-Yang Li; Wan-Ying Liu; Lin Zhang; Jin-Zhen Wu
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

4.  Diurnal triglyceridemia in relation to alcohol intake in men.

Authors:  Ana Torres do Rego; Boudewijn Klop; Erwin Birnie; Jan Willem F Elte; Victoria Cachofeiro Ramos; Luis A Alvarez-Sala Walther; Manuel Castro Cabezas
Journal:  Nutrients       Date:  2013-12-16       Impact factor: 5.717

5.  Quantile-dependent expressivity of postprandial lipemia.

Authors:  Paul T Williams
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

Review 6.  Genetic Regulatory Networks of Apolipoproteins and Associated Medical Risks.

Authors:  Preethi Basavaraju; Rubadevi Balasubramani; Divya Sri Kathiresan; Ilakkiyapavai Devaraj; Kavipriya Babu; Vasanthakumar Alagarsamy; Vinayaga Moorthi Puthamohan
Journal:  Front Cardiovasc Med       Date:  2022-01-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.